Recognition, diagnosis, and treatment of restless legs syndrome

Journal of the American Academy of Nurse Practitioners

Volumn 20, Issue 8, 2008, Pages 396-401

  Smith, Jennifer E ^a   Tolson, Jerry M ^b  

^a Walla Walla Clinic   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Diagnosis; Restless legs syndrome; Symptoms; Treatment

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ANAMNESIS; COST OF ILLNESS; HOSPITALIZATION; HUMAN; METHODOLOGY; NURSE ATTITUDE; NURSE PRACTITIONER; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PREVALENCE; PRIMARY HEALTH CARE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW;

COST OF ILLNESS; DOPAMINE AGONISTS; HUMANS; MEDICAL HISTORY TAKING; NURSE PRACTITIONERS; NURSE'S ROLE; NURSING ASSESSMENT; PREVALENCE; PRIMARY HEALTH CARE; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX;

EID: 49349090405     PISSN: 10412972     EISSN: 17457599     Source Type: Journal    
DOI: 10.1111/j.1745-7599.2008.00337.x     Document Type: Review

References (38)

1. Abetz, L., Allen, R., Follet, A., Washburn, T., Earley, C., Kirsch, J., et al 2004). Evaluating the quality of life of patients with restless legs syndrome. Clinical Therapeutics, 26, 925 935.
2. Allen, R., Becker, P. M., Bogan, R., Schmidt, M., Kushida, C. A., Fry, J. M., et al 2004). Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep, 27, 907 914.
3. Allen, R. P. Earley, C. J 1996). Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep, 19, 205 213.
4. Allen, R. P. Earley, C. J 2001). Restless legs syndrome: A review of clinical and pathophysiologic features. Journal of Clinical Neurophysiology, 18, 128 147.
5. Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S. Montplaisir, J 2003). Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the national institutes of health. Sleep Medicine, 4, 101 119.
6. Allen, R. P., Walters, A., Montplaisir, J., Hening, W., Myers, A., Bell, T. J., et al 2005). Restless legs syndrome prevalence and impact. REST general population study. Archives of Internal Medicine, 165, 1286 1292.
7. Anonymous 2005). Restless legs syndrome. Treatments can ease troubling symptoms. Mayo Clinic Women's Healthsource, 9 (4 1 2.
8. Baseman, D. G., O'Suilleabhain, P. E., Reimold, S. C., Laskar, S. R., Baseman, J. G. Dewey, R. B., Jr. 2004). Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology, 63, 301 304.
9. Berger, K., Luedemann, J., Trenkwalder, C., John, U. Kessler, C 2004). Sex and the risk of restless legs syndrome in the general population. Archives of Internal Medicine, 164, 196 202.
10. Bogan, R. K., Fry, J. M., Schmidt, M. H., Carson, S. W. Ritchie, S 2006). Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo controlled clinical trial. Mayo Clinic Proceedings, 81, 17 27.
11. Brodeur, C., Montplaisir, J., Godbout, R. Marinier, R 1988). Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: A double-blind, controlled study. Neurology, 38, 1845 1848.
12. Cervenka, S., Palhagen, S., Comley, R., Panagiotidis, G., Cselenyi, Z., Matthews, J., et al 2006). Support for dopaminergic hypoactivity in restless legs syndrome: A PET study on D2-receptor binding. Brain, 129, 2017 2028.
13. Ferini-Strambi, L 2002). Restless legs syndrome augmentation and pramipexole treatment. Sleep Medicine, 3, S23 S25.
14. Hening, W., Walters, A. S., Allen, R. P., Montplaisir, J., Myers, A. Ferini-Strambi, L 2004). Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: The REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Medicine, 5, 237 246.
15. Horvath, J., Fross, R. D., Kleiner-Fisman, G., Lerch, R., Stalder, H., Liaudat, S., et al 2004). Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Movement Disorders, 19, 656 662.
16. Kaplan, P. W., Allen, R. P., Buchholz, D. W. Walters, J. K 1993). A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep, 16, 717 723.
17. Michaud, M., Soucy, J. P., Chabli, A., Lavigne, G. Montplaisir, J 2002). SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. Journal of Neurology, 249, 164 170.
18. Montplaisir, J., Boucher, S., Poirier, G., Lavigne, G., Lapierre, O. Lesperance, P 1997). Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria. Movement Disorders, 12, 61 65.
19. Montplaisir, J., Godbout, R., Poirier, G. Bedard, M. A 1986). Restless legs syndrome and periodic movements in sleep: Physiopathology and treatment with l-dopa. Clinical Neuropharmacology, 9, 456 463.
20. Montplaisir, J., Karrasch, J., Haan, J. Volc, D 2006). Ropinirole is effective in the long-term management of restless legs syndrome: A randomized, controlled trial. Movement Disorders, 21, 1627 1635.
21. Oboler, S. K., Prochazka, A. V. Meyer, T. J 1991). Leg symptoms in outpatient veterans. Western Journal of Medicine, 155, 256 259.
22. Oertel, W. H., Stiasny-Kolster, K., Bergtholdt, B., Hallstrom, Y., Albo, J., Leissner, L., et al 2007). Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Movement Disorders, 22, 213 219.
23. O'Hare, J. A., Abuaisha, F. Geoghegan, M 1994). Prevalence and forms of neuropathic morbidity in 800 diabetics. Irish Journal of Medical Science, 163, 132 135.
24. Ohayon, M. M. Roth, T 2002). Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. Journal of Psychosomatic Research, 53, 547 554.
25. Partinen, M., Hirvonen, K., Jama, L., Alakuijala, A., Hublin, C., Tamminen, I., et al 2006). Efficacy & safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose finding study - The PRELUDE study. Sleep Medicine, 7, 407 417.
26. Phillips, B., Young, T., Finn, L., Asher, K., Hening, W. Purvis, C 2000). Epidemiology of restless legs symptoms in adults. Archives of Internal Medicine, 160, 2137 2141.
27. Silber, M., Girish, M. Izurieta, R 2003). Pramipexole in the management of restless legs syndrome: An extended study. Sleep, 26, 819 821.
28. Silber, M. H., Ehrenberg, B. L., Allen, R. P., Buchfuhrer, M. J., Earley, C. J., Hening, W. A., et al 2004). An algorithm for the management of restless legs syndrome. Mayo Clinic Proceedings, 79, 916 922.
29. Sowers, J. R. Vlachakis, N 1984). Circadian variation in plasma dopamine levels in man. Journal of Endocrinological Investigation, 7, 341 345.
30. Trenkwalder, C., Garcia-Borreguero, D., Montagna, P., Lainey, E., De Weerd, A., Tidswell, P., et al 2004). Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12 week, randomized, placebo controlled study in 10 European countries. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 92 97.
31. Trenkwalder, C., Stiasny-Kolster, K., Kupsch, A., Oertel, W. H., Koester, J. Reess, J 2006). Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Movement Disorders, 21, 1404 1410.
32. Turjanski, N., Lees, A. J. Brooks, D. J 1999). Striatal dopaminergic function in restless legs syndrome: 18f-dopa and 11c-raclopride PET studies. Neurology, 52, 932 937.
33. Ulfberg, J., Nystrom, B., Carter, N. Edling, C 2001). Prevalence of restless legs syndrome among men aged 18 to 64 years: An association with somatic disease and neuropsychiatric symptoms. Movement Disorders, 16, 1159 1163.
34. Walters, A. S., Hening, W., Rubinstein, M. Chokroverty, S 1991). A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep, 14, 339 345.
35. Walters, A. S., Ondo, W. G., Dreykluft, T., Grunstein, R., Lee, D. Sethi, K 2004). Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Movement Disorders, 19, 1414 1423.
36. Winkelman, J., Sethi, K., Kushida, C., Becker, P., Koester, J., Cappola, J., et al 2006). Efficacy and safety of pramipexole in restless legs syndrome. Neurology, 67, 1034 1039.
37. Winkelman, J. W. Johnston, L 2004). Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Medicine, 5, 9 14.
38. Winkelmann, J., Prager, M., Lieb, R., Pfister, H., Spiegel, B., Wittchen, H. U., et al 2005). "Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. Journal of Neurology, 252, 67 71.